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To determine whether blood biomarkers of neuronal damage (neuroﬁlament light chain
[NfL]), muscle damage (creatine kinase [CK]), and muscle mass (creatinine) are altered in
spinal bulbar muscular atrophy (SBMA) and can be used as biomarkers for disease severity.
Methods
In this multicenter longitudinal prospective study, plasma and serum were collected from 2
cohorts of patients with SBMA in London, United Kingdom (n = 50), and Padova, Italy (n =
43), along with disease (amyotrophic lateral sclerosis [ALS]) and healthy controls, and levels of
plasma and serumNfL, CK, and creatinine were measured. Disease severity was assessed by the
SBMA Functional Rating Scale and the Adult Myopathy Assessment Tool at baseline and 12
and 24 months.
Results
Blood NfL concentrations were increased in ALS samples, but were unchanged in both SBMA
cohorts, were stable after 12 and 24 months, and were not correlated with clinical severity.
Normal NfL levels were also found in a well-established mouse model of SBMA. Conversely,
CK concentrations were signiﬁcantly raised in SBMA compared with ALS samples, and were
not correlated to the clinical measures. Creatinine concentrations were signiﬁcantly reduced in
SBMA, and strongly and signiﬁcantly correlated with disease severity.
Conclusions
While muscle damage and muscle mass biomarkers are abnormal in SBMA, axonal damage
markers are unchanged, highlighting the relevant primary role of skeletal muscle in disease
pathogenesis. Creatinine, but not CK, correlated with disease severity, conﬁrming its role as
a valuable biomarker in SBMA.
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Spinal and bulbar muscular atrophy (SBMA), also known as
Kennedy disease (KD), is a disabling adult onset neuromus-
cular disorder that aﬀects men and is primarily characterized
by slowly progressive weakness and wasting of bulbar and
limb muscles.1,2 SBMA is caused by the expansion of a CAG
repeat in the androgen receptor (AR) gene and is character-
ized by muscle denervation and loss of lower motor neurons
in the spinal cord and the brainstem. Signs of primary skeletal
muscle damage, such as muscle ﬁber splitting, ﬁber de-
generation, and centralized nuclei, are also present in SBMA,
and recent work showing that silencing of the mutation in
muscle is able to rescue the disease phenotype in disease
models has further highlighted the relevance of a primary
myopathic component in this disorder.3–9
No therapy is currently available for SBMA and an important
limitation to trials for promising therapeutic strategies has
been the lack of eﬀective outcome measures. Biomarkers to
measure disease progression and therapeutic responses are
therefore strongly needed.
Neuroﬁlament light chain (NfL) has been found to be in-
creased in serum and plasma of numerous neurologic con-
ditions, including amyotrophic lateral sclerosis (ALS) and
inherited peripheral neuropathies, and to be a promising tool
to monitor disease progression.10,11 We here use the cur-
rently most sensitivemethodology tomeasure NfL in patients
with SBMA and in a rodent model of disease,12 and com-
pare this marker of neuronal damage with measures of muscle
damage and loss.
Methods
Standard protocol approvals, registrations,
and patient consents
Plasma and serum were prospectively collected with informed
consent from 2 cohorts of patients with a genetically con-
ﬁrmed diagnosis of SBMA attending the KD clinic at the
National Hospital for Neurology in London, United Kingdom
(n = 50), and at the University Hospital in Padova, Italy (n =
43). Samples from patients with ALS (n = 53) and healthy
relatives of patients (n = 73) were collected in neuromuscular
clinics in the same centers.
Approvals were obtained from the East London and the
City Research Ethics Committee (09/H0703/27). Written
informed consent was obtained from all participants in the
study.
Patient evaluation
All patients were recruited in neuromuscular clinics at the
National Hospital for Neurology in London, United Kingdom,
and at the University Hospital in Padova, Italy. All participants
with SBMA carried a pathogenic expansion of the CAG tri-
nucleotide repeat (>38 repeats) in the AR gene. ALS cases all
were recruited according to El Escorial probable and deﬁnite
ALS criteria. Controls were recruited in both centers in order to
reduce sources of bias. Healthy controls were excluded if they
had coexistent neurologic disease as determined by a symptom
and medical history–based questionnaire.
SBMA and ALS disease severity and progression were eval-
uated using functional rating scale scores (Spinal and Bulbar
Muscular Atrophy Functional Rating Scale [SBMAFRS],
Amyotrophic Lateral Sclerosis Functional Rating Scale
[ALSFRS]), and patients with SBMA were further evaluated
with the Adult Myopathy Assessment Tool (AMAT).13–15
Progression rate in patients with ALS was calculated as pro-
gression rate to last visit (PRL). This was the ALSFRS–revised
(range 1–48, with lower scores corresponding to higher level
of neurologic impairment) approximated to 48 at onset minus
the score at last visit divided per disease duration expressed in
month (ALS-Fast = PRL >1; ALS-Slow = PRL <0.5).
Sample collection and processing
Samples were processed, stored, and analyzed as previously
described.10,11 Blood samples from all participants were col-
lected into EDTA-containing tubes and centrifuged at 20°C at
3,500 rpm for 10 minutes within 1 hour. Repeat samples were
taken after 1 and 2 years, when available. Plasma and serum
were aliquoted and stored at −80°C.
Mouse samples
All experimental procedures were carried out under license
from the UK Home Oﬃce (Scientiﬁc Procedures Act 1986),
and following approval by the Ethical Review Panel of UCL
Institute of Neurology. Yeast artiﬁcial chromosome (YAC)
AR100 mice, which express at endogenous levels the human
androgen receptor with an expanded CAG repeat,12 were
bred andmaintained at UCL Institute of Neurology Biological
Services. Heterozygote males carrying the androgen receptor
with 100 polyglutamine repeats (pathogenic AR100 mice)
were mated with wild-type C57BL/6J females. Only male
mice were used in this study and male age-matched wild-type
littermates were used as controls. Mouse plasma was obtained
from male AR100 mice and controls at 18 months of age, as
previously described.12,16
Glossary
ALS = amyotrophic lateral sclerosis; ALSFRS = Amyotrophic Lateral Sclerosis Functional Rating Scale; AMAT = Adult
Myopathy Assessment Tool; AR = androgen receptor; CK = creatine kinase; KD = Kennedy disease; LMN = lower motor
neuron; NfL = neuroﬁlament light chain; PRL = progression rate to last visit; SBG = streptavidin-β-galactosidase; SBMA =
spinal and bulbar muscular atrophy; SBMAFRS = Spinal and Bulbar Muscular Atrophy Functional Rating Scale.
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NfL, creatine kinase (CK), and
creatinine measurements
The quantitative determination of NfL in human plasma (UK
cohort) and serum (Italian cohort) was undertaken by single
molecule array (Simoa) technology using a digital immuno-
assay Simoa HD-1 Analyzer (Quanterix; Lexington, MA)
using a commercially available NfL kit from the same vendor.
Plasma samples from KD, ALS-Fast, ALS-Slow, and healthy
patients, along with KD/WT mice, were equally distributed
on each plate and measured in duplicate. Each plate contained
a target-speciﬁc calibrator (500–0.686 pg/mL) and 2 quality
controls (10 and 200 pg/mL).
In the ﬁrst step, anti-NfL-antibody–coated paramagnetic cap-
ture beads, sample, and biotinylated detector antibody are
combined. NfL molecules present in the sample are cap-
tured by the anti-NfL-antibody–coated capture beads and
labeled with biotinylated detector antibodies. After washing,
a conjugate of streptavidin-β-galactosidase (SBG) ismixed with
the capture beads. SBG binds to the biotinylated detector
antibodies, resulting in enzyme labeling of captured NfL. CK
and creatinine were measured as part of routine clinical testing.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0
(GraphPad; La Jolla, CA). Patient NfL, CK, and creatinine
concentrations were compared using analysis of variance and
Bonferroni correction for multiple testing. Mouse NfL levels
were compared using Mann-Whitney test. Correlations of CK
and creatinine levels with SBMAFRS and AMAT scores were
assessed using Spearman correlation coeﬃcients. We included
all available samples for this study, given the rarity of the disease
and the unknown variability and changes of NfL in SBMA prior
to this work. Missing data were omitted from analysis—all
numbers for each analysis are reported in the table.
Data availability
Anonymized data not published within this article will be
made available by request from any qualiﬁed investigator.
Results
Cohorts
The study included 93 patients with SBMA, 53 patients with
ALS, and 73 healthy controls. Participant characteristics are
summarized in the table.
NfL levels are unchanged in 2 cohorts of
patients with SBMA
We measured the plasma levels of NfL, using the highly
sensitive Simoa assay, in samples from the UK SBMA cohort,
and compared them with healthy controls and with slow and
fast progressor ALS cases, as positive controls. While fast and
slow ALS progressors showed the previously described11 in-
crease in NfL levels (p < 0.0001 and p = 0.0008, respectively),
we detected no signiﬁcant increase in the SBMA cases (p =
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(p > 0.99) (ﬁgure 1A). We further examined whether levels
changed longitudinally at 12 (n = 28) and 24 (n = 8) months,
and showed NfL levels to be stable across this time, with the
exception of 3/28 cases where levels increased to >58 pg/mL,
the 95th percentile of controls (ﬁgure 1B).
NfL levels are unchanged in a mouse model
of disease
We assessed NfL levels in a well-established SBMA mouse
model: AR100mice. These mice express a 100-CAG expansion
in the human AR and develop a late-onset progressive neuro-
muscular phenotype characterized by muscle atrophy and
motor neuron degeneration, with no motor neuron loss at 6
months, and a 40% loss of motor neurons at 18 months of age
(B. Malik and L. Greensmith, personal written communication,
July 30, 2018, and references 12 and 17). NfL measurements
performed on the same platform as for the human samples did
not show a signiﬁcant increase in AR100 mice at 18 months vs
littermate controls (n = 9; p = 0.45) (ﬁgure 1C).
NfL levels are not increased in blood-derived bioﬂuids from 2
independent SBMA cohorts and a well-established mouse
model of disease.
Muscle damage and muscle mass markers are
significantly altered in SBMA
We investigated the levels of markers of muscle damage
(CK) and muscle mass (creatinine) in our patient cohorts
using standard clinical diagnostic assays. CK levels showed
remarkably similar values in both the UK and Italian cohorts
(mean 951 and 940 U/L, respectively), and were signiﬁ-
cantly increased compared to both healthy controls (mean
122 U/L, p < 0.0001 for both UK and Italian cohorts) and
ALS (p < 0.0001 for both UK and Italian cohorts vs slow and
fast progressing ALS). Interestingly, CK levels, diﬀerently from
NfL, did not diﬀer between slow and fast progressing ALS
(mean 699 and 701 U/L, respectively, p > 0.99) (ﬁgure 2A).
Creatinine levels were very similar in UK and Italian cohorts
and signiﬁcantly decreased compared to controls and ALS
(ﬁgure 2C).
Creatinine levels correlate with SBMA severity
To evaluate disease severity, we used the SBMAFRS, a function
rating scale developed for SBMA, and the AMAT score, which
detects deﬁcits in functional muscle performance and endur-
ance and has been used as an outcome measure for SBMA
clinical trials.13–15 While no signiﬁcant correlation was present
between clinical measures and CK (ﬁgure 2B), creatinine levels
strongly inversely correlated with both SBMAFRS and AMAT
in both SBMA cohorts (ﬁgure 2D).
Discussion
We show that NfL concentration in blood is unchanged in
patients with SBMA compared with controls, and concen-
trations do not change over time and are not related to disease
severity. The result was conﬁrmed in a well-established mouse
model of SBMA. This is surprising given that NfL has been
described to be increased in numerous neurodegenerative
conditions and mouse models, and cannot simply be imputed
solely to the slowly progressive nature of SBMA, as a recent
study using the same technique has detected an NfL increase
in Charcot-Marie-Tooth disease, another very slowly pro-
gressive neuromuscular condition.10,11,16,18,19
Conversely, markers of muscle damage (CK) and muscle mass
(creatinine) are aberrant in SBMA. CK is elevated compared to
both controls and ALS cases, and does not correlate to clinical
measures, possibly due to its reﬂection of more acute muscle
damage, whereas creatinine is reduced and signiﬁcantly corre-
lates with disease severity. A decrease in creatinine has also
been shown in a Japanese SBMA cohort to correlate with grip
strength and 6-minute walk distance and has also been shown
Figure 1 Neurofilament light chain (NfL) levels are unchanged in spinal and bulbar muscular atrophy (SBMA)
(A) NfL concentrations (pg/mL) from the UK cohort (plasma, UK control [CTR], UK SBMA, slow amyotrophic lateral sclerosis [ALS], and fast ALS) and the Italian
cohort (IT CTR and IT SBMA). Assays were conducted together, but statistical analysis (analysis of variance, Bonferroni multiple comparison correction) is
represented only between samples from the same cohort. (B) NfL concentrations in the longitudinal study in the UK cohort. Twelve-month (n = 28) and 24-
month (n = 8) timepoints represent 12 ± 2 and 24 ± 2 months. (C) NfL levels from AR100 (SBMA) and littermate control (WT) mice are shown (Mann-Whitney
test). Columns indicate mean, error bars indicate SD; ***p < 0.001; ****p < 0.0001; ns p > 0.05.
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to be lower in patients with SBMA than in patients with ALS
who have comparable wasting of muscle mass.20,21
Traditionally SBMA has been considered a lower motor neu-
ron (LMN) disease. Indeed, denervation is a crucial neuro-
physiology ﬁnding, and loss of LMN in postmortem tissue has
been well-documented.2,22Muscle abnormalities and CK levels
elevated beyond those found in ALS have been described in
early case series of this disease.23 Nonetheless, only recently,
analysis of SBMA muscle biopsies, and functional work spe-
ciﬁcally exploring the role of muscle in mouse models, have led
to acknowledging a primary muscle component to be relevant
for disease progression and pathogenesis alongside the neu-
rogenic component,3–9 and our ﬁndings support this.
Finally, SBMA and ALS are in diﬀerential diagnosis, and
a substantial proportion of patients with SBMA initially re-
ceive a diagnosis of ALS, causing distress.24 Although genetic
clinical testing is the gold standard for SBMA diagnosis, the
ﬁnding of normal levels of NfL in SBMA could be used in
a diagnostic panel of biochemical markers to help diﬀerentiate
patients presenting with motor neuron deﬁcits.
NfL concentrations in blood were unchanged in 2 cohorts of
patients with SBMA and in a mouse model of disease, while
markers of muscle damage and mass were altered, the latter
showing correlation with clinical measures of disease, sug-
gesting that biomarkers of muscle damage and mass, rather
than neuronal damage, should be used to monitor disease pro-
gression and outcome. This is consistent with previous obser-
vations that a primary myopathic component plays a primary
role in the disorder3–9 and supports the development of novel
disease-modifying agents towards the muscle target and the in-
corporation ofmuscle biomarkers to objectively assess outcomes
in therapeutic trials in SBMA.
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